Reuters logo
BRIEF-Genentech says FDA approves Rituxan Hycela for subcutaneous injection in certain blood cancers
June 22, 2017 / 6:48 PM / 5 months ago

BRIEF-Genentech says FDA approves Rituxan Hycela for subcutaneous injection in certain blood cancers

June 22 (Reuters) - Genentech :

* FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers

* Genentech - Rituxan Hycela will be available to people in United States within one to two weeks, and intravenous Rituxan will continue to be available Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below